Team EIT

Oncology

Team EIT

New Strategies to Enhance the Immunogenicity of Tumors

Cells with hypermutation phenotypes harbor an initial growth advantage to form primary tumors. However, this group of tumors produces more tumor-specific antigens that evoke immune responses. Contrarily, tumors that exhibit a low mutator phenotype avoid de novo mutations that would be deleterious to cellular fitness and, most importantly, evade immune surveillance. As a result, these patients harbor weaker immunogenic phenotypes with immune cell-poor tumor microenvironments, limiting the response rate to immunotherapies.

This team’s main objective is to identify how DNA damage response (DDR) shapes the tumor microenvironment. Using colorectal cancer as a model, this team will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. The main aim of the project will be to identify canonical and non-canonical roles of DDR molecules involved in tumor immunity. Our final goal is to design new therapeutic targets that promote a favorable tumor microenvironment for immunotherapies.

Mentors
  • Dr. Weixiao Sha (Industry mentor)
    Associate Scientific Director, Tumor Immunology Research at Merck
  • Dr. Balca Mardin (Industry mentor)
    Head of Laboratory, DNA Damage Response Research at Merck
  • TBD (Academic mentor)
The research of this team is kindly sponsored by Merck.

Dr. Semih Akincilar

Group Leader

 Short Bio
  • 2020 – 2024: Senior Scientist investigating the deregulation of inflammatory pathways in chronic inflammatory disorders at the Agency for Science, Technology, and Research (A*STAR), Singapore
  • 2017 – 2020: Postdoctoral Research Fellow in targeting replicative immortality in cancer cells at A*STAR, Singapore
  • 2013 – 2017: PhD in Biochemistry, National University of Singapore, investigated the transcriptional reactivation of telomerase gene in cancer
 Contact

Team EIT Alumni

At BioMed X we care for the people who work with us. Staying in touch with those who left but mainly contributed to BioMed X’s success is key. That’s why they have their designated place on our website. So let’s keep connected!